Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Increased Anti-Proliferation Performance of NanoChitosan-Moringa Seeds Extract and Co-Treatment with Doxorubicin in Liver Cancer Cells

HAYATI Journal of Biosciences · Vol. 32 No. 2 (2024) · hlm. 414–425

DOI
10.4308/hjb.32.2.414-425
ISSN
2086-4094, 1978-3019
Terbit
2024-12-30
Penerbit
Bogor Agricultural University, Indonesia
Bahasa
eng

Abstrak

Hepatocellular carcinoma (HCC) with high epidemiological report data. Pathogenesis in HCC also involves several signaling pathways. This study aims to evaluate the in vitro activity of Moringa seed NanoChitosan against Hep G2 liver cancer cells and Co-Treatment with Doxorubicin. Initially, nanoparticles were prepared by extracting Moringa seeds, formulating them into nano chitosan, and then characterizing the compounds and particle sizes. The IC50 dose was investigated using the MTT assay. Then, the IC50 dose was confirmed in more detail through immunofluorescence, betatrophin gene, several genes in the Wnt-βcatenin-CyclinD1 proliferation pathway, and the addition of the apoptotic effector Caspase-3 using RT-qPCR analysis. Each treatment used a single dose of NCH-Mosee and co-treatment or combination with 4 μg/ml doxorubicin. The IC50 dose was 994 μg/ml in single treatment and 649 μg/ml in combined treatment with Dox. Hep G2 showed a decrease in the expression level of each parameter measured with increasing single dose and combination treatment (p < 0.050). Histologically, cells shrank, betatrophin expression was inhibited, and luminescence was seen, which decreased with increasing dose. In conclusion, NCH-Mosee with dose-tracking toxicity combined with Dox can suppress the viability of Hep G2 cells.

Jaringan kolaborasi para penulis

40 penulis · 135 tautan kepenulisan bersama · 9 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • State University of Malang
  • National Yang Ming Chiao Tung University
  • National Research and Innovation Agency
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Siti ZubaidahState University of Malang5
Sri Rahayu LestariAfiliasi tidak diketahui5
Susriyati MahanalState University of Malang3
Yunita RakhmawatiAfiliasi tidak diketahui2
Sunaryono SunaryonoState University of Malang2
Dewi Sekar MiasihAfiliasi tidak diketahui2
Yuslinda AnnisaAfiliasi tidak diketahui2
Hadi SuwonoState University of Malang1
Herawati SusiloState University of Malang1
Herwim Enggar PratiwiState University of Malang1
Ahsan YunusAfiliasi tidak diketahui1
Desi FitriyaniAfiliasi tidak diketahui1
Achmad SlametAfiliasi tidak diketahui1
Najib MohammedAfiliasi tidak diketahui1
Rony IrawantoNational Research and Innovation Agency1
Muhammad Sasmito DjatiAfiliasi tidak diketahui1
Hidajah RachmawatiAfiliasi tidak diketahui1
Alif Rosyidah El BarorohAfiliasi tidak diketahui1
Markus DiantoroAfiliasi tidak diketahui1
Lisa Ainun NajihahAfiliasi tidak diketahui1
Abdulloh FuadAfiliasi tidak diketahui1
Subakti SAfiliasi tidak diketahui1
Arif HidayatAfiliasi tidak diketahui1
Sri Endah IndriwatiState University of Malang1
Dewi MurniAfiliasi tidak diketahui1
Paidi PaidiAfiliasi tidak diketahui1
Hardianto HardiantoAfiliasi tidak diketahui1
Sitoresmi PrabaningtyasAfiliasi tidak diketahui1
Hidayati MaghfirohAfiliasi tidak diketahui1
Arbin Janu SetiyowatiAfiliasi tidak diketahui1
Muhammad SaefiAfiliasi tidak diketahui1
Adisti RatnapuriAfiliasi tidak diketahui1
Nindiana Choirunisa'Afiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://journal.ipb.ac.id/index.php/hayati/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Increased Anti-Proliferation Performance of NanoChitosan-Moringa Seeds Extract and Co-Treatment with Doxorubicin in Liver Cancer Cells</dc:title>
	<dc:creator xml:lang="en">Susanto, Hendra</dc:creator>
	<dc:creator xml:lang="en">Sholeh, Moch</dc:creator>
	<dc:creator xml:lang="en">Tri Endharti, Agustina </dc:creator>
	<dc:creator xml:lang="en">Nik Malek, Nik Ahmad Nizam</dc:creator>
	<dc:creator xml:lang="en">Amaliyah Firdaus, Sa’diyatul Rizqie </dc:creator>
	<dc:creator xml:lang="en">Yuda Handaya, Adeodatus</dc:creator>
	<dc:creator xml:lang="en">Taufiq, Ahmad</dc:creator>
	<dc:description xml:lang="en">Hepatocellular carcinoma (HCC) with high epidemiological report data. Pathogenesis in HCC also involves several signaling pathways. This study aims to evaluate the in vitro activity of Moringa seed NanoChitosan against Hep G2 liver cancer cells and Co-Treatment with Doxorubicin. Initially, nanoparticles were prepared by extracting Moringa seeds, formulating them into nano chitosan, and then characterizing the compounds and particle sizes. The IC50 dose was investigated using the MTT assay. Then, the IC50 dose was confirmed in more detail through immunofluorescence, betatrophin gene, several genes in the Wnt-βcatenin-CyclinD1 proliferation pathway, and the addition of the apoptotic effector Caspase-3 using RT-qPCR analysis. Each treatment used a single dose of NCH-Mosee and co-treatment or combination with 4 μg/ml doxorubicin. The IC50 dose was 994 μg/ml in single treatment and 649 μg/ml in combined treatment with Dox. Hep G2 showed a decrease in the expression level of each parameter measured with increasing single dose and combination treatment (p &amp;lt; 0.050). Histologically, cells shrank, betatrophin expression was inhibited, and luminescence was seen, which decreased with increasing dose. In conclusion, NCH-Mosee with dose-tracking toxicity combined with Dox can suppress the viability of Hep G2 cells.</dc:description>
	<dc:publisher xml:lang="en">Bogor Agricultural University, Indonesia</dc:publisher>
	<dc:date>2024-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://journal.ipb.ac.id/hayati/article/view/58913</dc:identifier>
	<dc:identifier>10.4308/hjb.32.2.414-425</dc:identifier>
	<dc:source xml:lang="en">HAYATI Journal of Biosciences; Vol. 32 No. 2 (2025): March 2025; 414-425</dc:source>
	<dc:source>2086-4094</dc:source>
	<dc:source>1978-3019</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://journal.ipb.ac.id/hayati/article/view/58913/29816</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2025 Hendra Susanto, Moch Sholeh, Agustina  Tri Endharti, Nik Ahmad Nizam Nik Malek, Sa’diyatul Rizqie  Amaliyah Firdaus, Adeodatus Yuda Handaya, Ahmad Taufiq</dc:rights>
</oai_dc:dc>